- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00405418
Lantus Versus Levemir Treat-To-Target (L2T3)
Target Glycemic Control and the Incidence of Documented Symptomatic Hypoglycemia in Insulin naïve Subjects With Type 2 Diabetes Failing on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or Insulin Detemir.
Primary objective:
To demonstrate the non-inferiority of insulin glargine in comparison to insulin detemir in term of percentage of patients who reach the target of HbA1c < 7% at the end of the treatment period and do not experience symptomatic hypoglycemia, confirmed by plasma glucose (PG) ≤ 56 mg/dL (3.1 mmol/L)
Secondary objectives:
- To compare between the 2 treatment groups, the percentage of patients who reach the target of HbA1c < 7% and < 6.5% at the end of the treatment period
- To compare the changes in HbA1c and fasting plasma glucose (FPG)
- To compare the evolution of blood glucose profiles
- To compare the day to day FPG variability, the insulin doses
- To determine in each treatment group the biochemical and patient-related determinants of failure to reach HbA1c targets
- To compare the overall incidence and rate of symptomatic hypoglycemia and nocturnal symptomatic hypoglycemia confirmed by PG ≤ 56 mg/dL (3.1 mmol/L)
- To compare over the treatment period, the overall incidence and rate of symptomatic hypoglycemia and symptomatic nocturnal hypoglycemia (with PG ≤ 70 mg/dL [3.9 mmol/L]), of symptomatic day-time hypoglycemia (with PG ≤ 70 mg/dL and with PG ≤ 56 mg/dL), of severe hypoglycemia, of asymptomatic hypoglycemia with PG ≤ 56 mg/dL
- To compare the overall safety: incidence of adverse events (including serious hypoglycemia and local tolerance at injection site), change in body weight, in waist circumference and in waist / hip ratio
- To assess the quality of life and treatment satisfaction
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 4
Kontakty a umístění
Studijní místa
-
-
-
North Ryde, Austrálie
- Sanofi-Aventis
-
-
-
-
-
Sao Paolo, Brazílie
- Sanofi-Aventis
-
-
-
-
-
Hoersholm, Dánsko
- Sanofi-Aventis
-
-
-
-
-
Helsinki, Finsko
- Sanofi-Aventis
-
-
-
-
-
Gouda, Holandsko
- Sanofi-Aventis
-
-
-
-
-
Mumbai, Indie
- Sanofi-Aventis
-
-
-
-
-
Dublin, Irsko
- Sanofi-Aventis
-
-
-
-
-
Laval, Kanada
- Sanofi-Aventis
-
-
-
-
-
Seoul, Korejská republika
- Sanofi-Aventis
-
-
-
-
-
Istanbul, Krocan
- Sanofi-Aventis
-
-
-
-
-
Berlin, Německo
- Sanofi-Aventis
-
-
-
-
-
Porto Salvo, Portugalsko
- Sanofi-Aventis
-
-
-
-
-
Bucharest, Rumunsko
- Sanofi-Aventis
-
-
-
-
-
Moscow, Ruská Federace
- Sanofi-Aventis
-
-
-
-
-
Guildford, Spojené království
- Sanofi-Aventis
-
-
-
-
-
Belgrade, Srbsko
- Sanofi-Aventis
-
-
-
-
-
Taipe, Tchaj-wan
- Sanofi-Aventis
-
-
-
-
-
Barcelona, Španělsko
- Sanofi-Aventis
-
-
-
-
-
Stockholm, Švédsko
- Sanofi-Aventis
-
-
-
-
-
Meyrin, Švýcarsko
- Sanofi-Aventis
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Type 2 diabetes for at least 1 year
- Insulin naïve
- Treated with stable doses of oral antidiabetics for at least 3 months prior to study start, including at least metformin (at least 1g/day)
- 7% ≤ HbA1c ≤ 10.5 %
- Body mass index (BMI) < 40 kg/m²
- Ability and willingness to perform blood glucose monitoring using a blood glucose meter and to use a patient diary
Exclusion Criteria:
- Type 1 diabetes
- Current or previous use of insulin (except for previous treatment of gestational diabetes or brief treatment with insulin for less than 1 week)
- Treatment with glucagon-like peptide (GLP)-1 receptor agonists or with dipeptidyl peptidase (DPP)-IV inhibitors
- Active proliferative diabetic retinopathy, as defined by the application of photocoagulation or surgery, in the 6 months before study entry or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgery during the study (an optic fundus examination should have been performed in the 2 years prior to study entry)
- Pregnancy (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraceptive method)
- Breast-feeding
- History of hypersensitivity to the study drugs or to drugs with a similar chemical structure
- Treatment with systemic corticosteroids in the 3 months prior to study entry
- Treatment with any investigational product in the 2 months prior to study entry
- Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol
- Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult
- Impaired hepatic function as shown by Alamine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) greater than three times the upper limit of normal range at study entry
- Impaired renal function as shown by serum creatinine ≥ 1.5 mg/dL (≥ 133 μmol/L) in men and ≥ 1.4 mg/dL (124 μmol/L) in women at study entry
- History of drug or alcohol abuse in the last year
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: 1
Insulin Glargine
|
Subcutaneous injection, once a day in the evening
|
Aktivní komparátor: 2
Insulin Detemir
|
Subcutaneous injection, twice a day at breakfast and before dinner
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
HbA1c recorded
Časové okno: At baseline, week 12 and week 24
|
At baseline, week 12 and week 24
|
Self-monitored fasting BG in both treatment arms and pre-dinner BG in detemir arm
Časové okno: On the 4 consecutive days before each visit
|
On the 4 consecutive days before each visit
|
Self-monitored BG values from 8-point 24-hour profile recorded on 2 consecutive days
Časové okno: Within the week prior to baseline, week 12 and week 24
|
Within the week prior to baseline, week 12 and week 24
|
Episodes of hypoglycemia (symptomatic, total and categorized as day-time/nocturnal, severe or asymptomatic)
Časové okno: All across the study
|
All across the study
|
Self-monitored BG values whenever patient experiences symptoms possibly related to hypoglycemia.
Časové okno: All across the study
|
All across the study
|
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
Doses of insulin glargine or insulin detemir
Časové okno: Daily
|
Daily
|
Laboratory fasting plasma glucose
Časové okno: At baseline, week 12 and week 24
|
At baseline, week 12 and week 24
|
Insulinemia and fasting C-peptide level
Časové okno: At baseline
|
At baseline
|
Lipid profile
Časové okno: at baseline and week 24
|
at baseline and week 24
|
Patient reported outcomes (quality of life and treatment satisfaction)
Časové okno: at baseline, week 4, week 12 and at the last visit
|
at baseline, week 4, week 12 and at the last visit
|
Safety data: occurrence of adverse events and weight
Časové okno: assessed at each visit
|
assessed at each visit
|
Waist and hip circumferences
Časové okno: measured at baseline, week 12 and week 24
|
measured at baseline, week 12 and week 24
|
Systolic and diastolic blood pressure
Časové okno: measured at study entry, baseline, week 12 and week 24
|
measured at study entry, baseline, week 12 and week 24
|
Physical examination
Časové okno: performed at study entry and at last visit.
|
performed at study entry and at last visit.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Ředitel studie: Valérie Pilorget, Sanofi
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- LANTU_C_00579
- EUDRACT # : 2006-000324-13
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Diabetes mellitus, typ 2
-
Hoffmann-La RocheDokončenoDiabetes 2. typu, Diabetes 1. typuRakousko, Spojené království
-
Services Hospital, LahoreDokončeno
-
Griffin HospitalCalifornia Walnut CommissionDokončenoDIABETES MELLITUS TYP 2Spojené státy
-
West China HospitalDokončeno
-
University of Roma La SapienzaNeznámýDiabetes Mellitus Typ 2 Reaktivita krevních destiček StatinItálie
-
Bristol-Myers SquibbDokončenoDiabetes, typ 2Spojené státy, Kanada, Mexiko, Portoriko, Austrálie, Polsko, Tchaj-wan
-
Universidade Federal de Ouro PretoDokončeno
-
Kyowa Kirin Co., Ltd.Dokončeno
-
Novo Nordisk A/SNáborDiabetes, typ 2Spojené státy, Indie, Španělsko, Polsko, Jižní Afrika, Bulharsko, Německo, Japonsko, Portoriko
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Churchill HospitalDokončenoDiabetes, typ 2Spojené království
Klinické studie na Insulin glargine
-
Stanford UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Aktivní, ne náborDiabetes typu 1Spojené státy